Tag-Free SARS-CoV-2 Receptor Binding Domain (RBD), but Not C-Terminal Tagged SARS-CoV-2 RBD, Induces a Rapid and Potent Neutralizing Antibody Response.

MLA

Lin, Ting-Wei, et al. “Tag-Free SARS-CoV-2 Receptor Binding Domain (RBD), but Not C-Terminal Tagged SARS-CoV-2 RBD, Induces a Rapid and Potent Neutralizing Antibody Response.” Vaccines, vol. 10, no. 11, Oct. 2022. EBSCOhost, https://doi.org/10.3390/vaccines10111839.

APA

Lin, T.-W., Huang, P.-H., Liao, B.-H., Chao, T.-L., Tsai, Y.-M., Chang, S.-C., Chang, S.-Y., & Chen, H.-W. (2022). Tag-Free SARS-CoV-2 Receptor Binding Domain (RBD), but Not C-Terminal Tagged SARS-CoV-2 RBD, Induces a Rapid and Potent Neutralizing Antibody Response. Vaccines, 10(11). https://doi.org/10.3390/vaccines10111839

Chicago

Lin, Ting-Wei, Ping-Han Huang, Bo-Hung Liao, Tai-Ling Chao, Ya-Min Tsai, Shih-Chung Chang, Sui-Yuan Chang, and Hui-Wen Chen. 2022. “Tag-Free SARS-CoV-2 Receptor Binding Domain (RBD), but Not C-Terminal Tagged SARS-CoV-2 RBD, Induces a Rapid and Potent Neutralizing Antibody Response.” Vaccines 10 (11). doi:10.3390/vaccines10111839.